Barbexaclone
Chemical compound
- N03AA04 (WHO)
- BR: Class B1 (Psychoactive drugs)[1]
- US: Schedule IV
- 4388-82-3
Y
- 71196
- DB09001
N
- 64332 Y
- 291GX1YB65
- DTXSID90195974
N
Y (what is this?) (verify)Barbexaclone (Maliasin) is a salt compound of phenobarbital and levopropylhexedrine.[2] It was introduced in 1983. It has been reported to be as effective as phenobarbital but better tolerated; however, as of 2004, these "promising results"[3] had not yet been confirmed nor denied in controlled trials.
Potency
100 mg of barbexaclone is equivalent to 60 mg of phenobarbital.[2]
References
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ a b Shorvon S, Perucca E, Engel Jr J (23 September 2015). The Treatment of Epilepsy. Wiley. pp. 1706–1707. ISBN 978-1-118-93699-3.
- ^ Salles Barbosa MF (September 1978). "[Barbexaclone in the treatment of cerebral dysrhythmia]". Arquivos de Neuro-Psiquiatria. 36 (3): 245–249. doi:10.1590/s0004-282x1978000300009. PMID 28716.
Further reading
- Shorvon SR, Fish DR, Perucca E, Dodson WE, eds. (2004). The Treatment of Epilepsy (2nd ed.). Published by Blackwell. p. 472. ISBN 0-632-06046-8.
- v
- t
- e
Anticonvulsants (N03)
| GABAAR PAMs |
|
|---|---|
| GABA-T inhibitors |
|
| Others |
modulators
| CA inhibitors |
|
|---|---|
| Others |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This sedative-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
